iNHL and MCL
Haematology · 2015–2015
1decision
1medicine
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bendamustine First-line treatment of Stage III-IV indolent Non-Hodgkin's Lymphoma (iNHL) and Stage III-IV Mantle Cell Lymphoma (MCL) in previously untreated patients, in… | Jul 2015 | Recommended with restriction | 2 individuals |
What the PBS pays
$7M in government benefit over 2024–25, across 11,482 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| bendamustine | $7.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.